November 30, 2016 - By kentuckypostne · 0 Comments
The stock of Cti Biopharma Corporation (NASDAQ:CTIC) registered a decrease of 2.87% in short interest. CTIC’s total short interest was 518,600 shares in November as published by FINRA. Its down 2.87% from 533,900 shares, reported previously. With 394,700 shares average volume, it will take short sellers 1 days to cover their CTIC’s short positions. The short interest to Cti Biopharma Corporation’s float is 0.26%. About 194,638 shares traded hands. CTI BioPharma Corp (NASDAQ:CTIC) has declined 19.23% since April 27, 2016 and is downtrending. It has underperformed by 24.46% the S&P500.
CTI BioPharma Corp. is a biopharmaceutical firm focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The company has a market cap of $113.46 million. The Firm is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It currently has negative earnings. It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis.
Insitutional Activity: The institutional sentiment increased to 0.6 in Q2 2016. Its up 0.15, from 0.45 in 2016Q1. The ratio increased, as 31 funds sold all CTI BioPharma Corp shares owned while 20 reduced positions. 14 funds bought stakes while 9 increased positions. They now own 81.51 million shares or 22.80% less from 105.59 million shares in 2016Q1.
Moreover, Advisory Services Ntwk Limited Liability Corporation has 0% invested in CTI BioPharma Corp (NASDAQ:CTIC) for 20 shares. Lmr Prns Ltd Liability Partnership last reported 235,048 shares in the company. Jacobs Levy Equity Inc holds 0.01% or 1.17M shares in its portfolio. Moreover, Morgan Stanley has 0% invested in CTI BioPharma Corp (NASDAQ:CTIC) for 50,574 shares. Washington Tru reported 410,616 shares or 0.01% of all its holdings. The Florida-based Ladenburg Thalmann Services has invested 0% in CTI BioPharma Corp (NASDAQ:CTIC). Oxford Asset Management last reported 82,300 shares in the company. Susquehanna Grp Inc Ltd Liability Partnership reported 43,765 shares or 0% of all its holdings. The Germany-based Deutsche Savings Bank Ag has invested 0% in CTI BioPharma Corp (NASDAQ:CTIC). Laurion Cap Mngmt L P last reported 0% of its portfolio in the stock. Panagora Asset Mgmt holds 0% or 45,270 shares in its portfolio. Exane Derivatives has 1 shares for 0% of their US portfolio. Vanguard Grp, a Pennsylvania-based fund reported 7.64M shares. Jane Street Group Limited Com holds 0% or 362,162 shares in its portfolio. Blair William & Company Il holds 0% of its portfolio in CTI BioPharma Corp (NASDAQ:CTIC) for 511,984 shares.
CTI BioPharma Corp. (CTI), incorporated on September 4, 1991, is a biopharmaceutical firm focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers. The Firm is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
More notable recent CTI BioPharma Corp (NASDAQ:CTIC) news were published by: Fool.com which released: “Why CTI BioPharma Corp. Came Crashing Down Today” on December 04, 2015, also Fool.com with their article: “Why CTI BioPharma Corp Shares Are Falling Today” published on October 27, 2015, Fool.com published: “Why CTI Biopharma Corp Is Soaring Today” on June 01, 2015. More interesting news about CTI BioPharma Corp (NASDAQ:CTIC) were released by: Prnewswire.com and their article: “CTI BioPharma Granted 180 Day Extension By NASDAQ To Regain Compliance With …” published on September 22, 2016 as well as Prnewswire.com‘s news article titled: “CTI BioPharma Announces Positive Progress Of Lead Clinical Programs And …” with publication date: January 11, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.